[{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ Sun Yat-sen University","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sun Yat-sen University | Tongji Hospital | Sichuan Cancer Hospital | The First Affiliated Hospital of Zhengzhou University | West China Hospital | Zhejiang University | Jilin Provincial Tumor Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ Sun Yat-sen University | Tongji Hospital | Sichuan Cancer Hospital | The First Affiliated Hospital of Zhengzhou University | West China Hospital | Zhejiang University | Jilin Provincial Tumor Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Sun Yat-sen University | Tongji Hospital | Sichuan Cancer Hospital | The First Affiliated Hospital of Zhengzhou University | West China Hospital | Zhejiang University | Jilin Provincial Tumor Hospital | Hunan Cancer Hospital | Shandong Cancer Hospital and"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Peking University People's Hospital | Henan Cancer Hospital | Nanfang Hospital, Southern Medical University | The First Affiliated Hospital of Soochow University | Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Pe","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TGRX-678","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ Peking University People's Hospital | Henan Cancer Hospital | Nanfang Hospital, Southern Medical University | The First Affiliated Hospital of Soochow University | Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Pe","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen TargetRx \/ Peking University People's Hospital | Henan Cancer Hospital | Nanfang Hospital, Southern Medical University | The First Affiliated Hospital of Soochow University | Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Pe"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TGRX-814","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ Institute of Hematology & Blood Diseases Hospital, China","highestDevelopmentStatusID":"7","companyTruncated":"Shenzhen TargetRx \/ Institute of Hematology & Blood Diseases Hospital, China"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ Sun Yat-sen University","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The First Affiliated Hospital of Bengbu Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ The First Affiliated Hospital of Bengbu Medical University","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ The First Affiliated Hospital of Bengbu Medical University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Peking University People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TGRX-678","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ Peking University People's Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen TargetRx \/ Peking University People's Hospital"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TGRX-678","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen TargetRx \/ MD Anderson Cancer Center"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TGRX-678","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Itraconazole","moa":"Cytochrome P450 51","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"The First Affiliated Hospital of Soochow University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Radiolabeled Compounds","year":"2024","type":"Inapplicable","leadProduct":"14-C TGRX-326","moa":"Bacterial DNA gyrase","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ The First Affiliated Hospital of Soochow University"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Sir Run Run Shaw Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TGRX-1942","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen TargetRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Shenzhen TargetRx \/ Sir Run Run Shaw Hospital","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen TargetRx \/ Sir Run Run Shaw Hospital"},{"orgOrder":0,"company":"Shenzhen TargetRx","sponsor":"Simcere Zaiming","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Deulorlatinib","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen TargetRx","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen TargetRx \/ Simcere Zaiming","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen TargetRx \/ Simcere Zaiming"}]
Find Clinical Drug Pipeline Developments & Deals by Shenzhen TargetRx
Sponsor :
Peking University People's Hospital | Henan Cancer Hospital | Nanfang Hospital, Southern Medical University | The First Affiliated Hospital of Soochow University | Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Pe
Sponsor :
Peking University People's Hospital | Henan Cancer Hospital | Nanfang Hospital, Southern Medical University | The First Affiliated Hospital of Soochow University | Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Pe
Details :
Simcere Zaiming will acquire exclusive commercial rights to TGRX-326, an ALK/ROS1 dual receptor tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC), in Mainland China.